Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYCNNASDAQ:DVAXNASDAQ:OPTNNASDAQ:PTGXNASDAQ:XERS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.14+13.4%$3.10$1.75▼$6.75$7.51M1.843,174 shs441 shsDVAXDynavax Technologies$11.17-2.2%$12.25$10.06▼$15.15$1.46B1.262.03 million shs1.92 million shsOPTNOptiNose$0.91-2.2%$1.47$0.86▼$2.10$101.95M-0.24832,803 shs23.36 million shsPTGXProtagonist Therapeutics$24.66-4.0%$28.37$13.72▼$33.34$1.44B2.01694,204 shs606,307 shsXERSXeris Biopharma$1.70-3.4%$2.32$1.46▼$3.26$238.77M2.332.13 million shs893,739 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+10.95%-2.43%+1.29%+7.17%-44.83%DVAXDynavax Technologies-2.19%-1.50%-9.70%-16.14%+5.88%OPTNOptiNose-2.19%-2.45%-38.85%-37.15%-49.72%PTGXProtagonist Therapeutics-4.05%-2.22%-11.93%-1.08%+6.02%XERSXeris Biopharma-3.41%-3.41%-17.07%-31.73%-21.66%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADVAXDynavax Technologies4.3313 of 5 stars3.41.00.04.72.32.51.9OPTNOptiNose4.0058 of 5 stars3.52.00.04.21.92.50.6PTGXProtagonist Therapeutics1.601 of 5 stars3.51.00.00.02.62.50.0XERSXeris Biopharma3.6471 of 5 stars3.52.00.04.20.02.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion TherapeuticsN/AN/AN/AN/ADVAXDynavax Technologies2.75Moderate Buy$25.00123.81% UpsideOPTNOptiNose3.00Buy$4.00341.99% UpsidePTGXProtagonist Therapeutics3.00Buy$36.0045.99% UpsideXERSXeris Biopharma3.00Buy$4.88186.76% UpsideCurrent Analyst RatingsLatest CYCN, DVAX, PTGX, OPTN, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/18/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $4.003/11/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$5.003/7/2024XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.50 ➝ $6.002/28/2024PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $37.002/28/2024PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.002/23/2024DVAXDynavax TechnologiesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/1/2024DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$1.62M5.25N/AN/A$4.62 per share0.68DVAXDynavax Technologies$232.28M6.29N/AN/A$4.81 per share2.32OPTNOptiNose$70.99M1.44N/AN/A($0.77) per share-1.18PTGXProtagonist Therapeutics$60M23.95N/AN/A$5.84 per share4.22XERSXeris Biopharma$163.91M1.46N/AN/A($0.05) per share-34.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)DVAXDynavax Technologies-$6.39M-$0.06N/A25.98N/A-2.75%-1.08%-0.66%5/8/2024 (Confirmed)OPTNOptiNose-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)PTGXProtagonist Therapeutics-$78.96M-$1.49N/AN/AN/AN/A-27.49%-25.30%5/2/2024 (Estimated)XERSXeris Biopharma-$62.26M-$0.45N/AN/AN/A-37.98%-610.76%-19.15%5/14/2024 (Estimated)Latest CYCN, DVAX, PTGX, OPTN, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/ADVAXDynavax Technologies-$0.04N/A+$0.04N/AN/AN/A 3/7/202412/31/2023OPTNOptiNose-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million 3/6/2024Q4 2023XERSXeris Biopharma-$0.09-$0.10-$0.01-$0.10$45.50 million$44.39 million 2/27/202412/31/2023PTGXProtagonist Therapeutics$0.05$0.44+$0.39$0.44$60.00 million$60.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A3.853.85DVAXDynavax Technologies0.4113.8112.96OPTNOptiNoseN/A0.600.55PTGXProtagonist TherapeuticsN/A16.7116.71XERSXeris Biopharma49.271.641.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%DVAXDynavax Technologies96.96%OPTNOptiNose85.60%PTGXProtagonist Therapeutics98.63%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics13.10%DVAXDynavax Technologies2.98%OPTNOptiNose2.20%PTGXProtagonist Therapeutics5.00%XERSXeris Biopharma4.36%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataDVAXDynavax Technologies408130.86 million126.96 millionOptionableOPTNOptiNose132112.65 million110.17 millionNot OptionablePTGXProtagonist Therapeutics11258.28 million55.36 millionOptionableXERSXeris Biopharma377140.45 million134.33 millionOptionableCYCN, DVAX, PTGX, OPTN, and XERS HeadlinesSourceHeadlineXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsfinance.yahoo.com - April 5 at 12:23 PMXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)finance.yahoo.com - April 3 at 6:23 PMXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 2 at 8:50 AMXeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimermarketbeat.com - March 28 at 8:29 AMXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growthproactiveinvestors.com - March 18 at 9:49 PMHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Resultsfinance.yahoo.com - March 9 at 1:59 PMXeris Biopharma (XERS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 8 at 7:43 PMXeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023finance.yahoo.com - March 7 at 2:41 PMXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 7 at 1:01 PMQ4 2023 Xeris Biopharma Holdings Inc Earnings Callfinance.yahoo.com - March 7 at 12:19 AMXeris Biopharma Shares Drop After Weak 4Q Resultsmarketwatch.com - March 6 at 7:18 PMXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84Mmsn.com - March 6 at 7:18 PMXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023investorplace.com - March 6 at 2:00 PMXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpproactiveinvestors.com - March 6 at 9:57 AMXeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimateszacks.com - March 6 at 9:16 AMXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Eventsbusinesswire.com - March 6 at 7:02 AMXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capitalbusinesswire.com - March 6 at 7:00 AMWhy Xeris (XERS) Might Surprise This Earnings Seasonzacks.com - March 5 at 10:46 AMXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024businesswire.com - February 28 at 7:00 AM3 Breakout Stocks Under $5 to Buy for More Upsidetheglobeandmail.com - February 23 at 7:13 PMXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conferencefinance.yahoo.com - February 5 at 9:27 AMBig Game or Small, Here's How to Go About Stalking a Traderealmoney.thestreet.com - February 3 at 6:45 PMXeris inks licensing deal with Amgen on former Horizon drugchicagobusiness.com - January 12 at 9:32 AMXeris Biopharma jumps on news of Amgen dealthepharmaletter.com - January 12 at 9:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Dynavax TechnologiesNASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.OptiNoseNASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Protagonist TherapeuticsNASDAQ:PTGXProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Xeris BiopharmaNASDAQ:XERSXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.